Kantarjian H - Search Results

1

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

Verstovsek S, Hoffman R, Mascarenhas J, Soria JC, Bahleda R, McCoon P, Tang W, Cortes J, Kantarjian H, Ribrag V. Verstovsek S, et al. Among authors: kantarjian h. Leuk Res. 2015 Feb;39(2):157-63. doi: 10.1016/j.leukres.2014.11.018. Epub 2014 Nov 29. Leuk Res. 2015. PMID: 25530567 Clinical Trial.

2

Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.

Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Robertson LE, et al. Among authors: kantarjian h. Leukemia. 1995 Jun;9(6):943-5. Leukemia. 1995. PMID: 7596181 Clinical Trial.

3

A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. Robertson LE, et al. Among authors: kantarjian h. Leukemia. 1995 Sep;9(9):1444-9. Leukemia. 1995. PMID: 7658710

4

Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.

Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S, Brown B, Keating MJ. Robertson LE, et al. Among authors: kantarjian h. Leukemia. 1994 Dec;8(12):2047-51. Leukemia. 1994. PMID: 7807993

5

Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.

Cortes J, O'Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Cortes J, et al. Among authors: kantarjian h. Leukemia. 1994 Dec;8(12):2174-8. Leukemia. 1994. PMID: 7808007

6

Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.

Cortes JE, Kantarjian H, O'Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Cortes JE, et al. Among authors: kantarjian h. Leukemia. 1995 Jan;9(1):115-7. Leukemia. 1995. PMID: 7845005

7

All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.

Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. Cortes JE, et al. Among authors: kantarjian h. Cancer. 1994 Jun 15;73(12):2946-52. doi: 10.1002/1097-0142(19940615)73:12<2946::aid-cncr2820731211>3.0.co;2-q. Cancer. 1994. PMID: 8199992 Clinical Trial.

8

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.

Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Estey E, et al. Among authors: kantarjian h. Leuk Lymphoma. 1993 Mar;9(4-5):343-50. doi: 10.3109/10428199309148532. Leuk Lymphoma. 1993. PMID: 8394169 Clinical Trial.

9

Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.

Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Cortes J, et al. Among authors: kantarjian h. Am J Med. 1996 Apr;100(4):452-5. doi: 10.1016/s0002-9343(97)89522-8. Am J Med. 1996. PMID: 8610733 Clinical Trial.

10

Chronic myelogenous leukemia: a review.

Cortes JE, Talpaz M, Kantarjian H. Cortes JE, et al. Among authors: kantarjian h. Am J Med. 1996 May;100(5):555-70. doi: 10.1016/s0002-9343(96)00061-7. Am J Med. 1996. PMID: 8644769 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,543 results

Search Page

Filters